Tenofovir/emtricitabine

From Self-sufficiency
Jump to: navigation, search
Tenofovir/emtricitabine
Combination of
Tenofovir Nucleotide analogue reverse transcriptase inhibitor
Emtricitabine Nucleoside reverse transcriptase inhibitor
Clinical data
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration
Oral
Legal status
Legal status
Identifiers
ATC code J05AR03 (WHO)
PubChem CID 11954236
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tenofovir/emtricitabine trademark Truvada, is a fixed dose combination of two antiretroviral drugs used for the treatment of HIV. It consists of 300 milligrams of tenofovir and 200 milligrams of emtricitabine. By combining the two agents into one tablet, it reduces the pill burden and increases compliance with antiretroviral therapy. The drug has also found some potential as a preventative measure if taken daily or weekly leading up to exposure, though human clinical trials are ongoing [1][2].

Clinical Studies

The HEAT study (Randomized, double-blind, placebo-matched, multicentre)showed that once-daily emtricitabine/tenofovir plus lopinavir/ritonavir or boosted atazanavir or efavirenz were effective in the initial treatment of patients with HIV-1 infection (with screening plasma HIV-1 RNA levels of <math>>=</math>1000000copies/mL in ACTG 5202).[1] In other randomized studies, emtricitabine/tenofovir DF 200 mg/300 mg once daily was an effective backbone for boosted PI-based regimens in the initial treatment of HIV-1 infection.[1] Emtricitabine/tenofovir DF in combination with various boosted PIs was generally well tolerated by adults with HIV-1 infection.[1]

Truvada was developed by Gilead Sciences and approved by the Untited States' Food and Drug Administration in 2004.

A combination pill containing Truvada and efavirenz (Sustiva) is also available and is marketed as Atripla.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
pt:Associação tenofovir/emtricitabine
  1. 1.0 1.1 1.2 Perry CM.[3].Drugs 2009;69(7):843-857.doi: 10.2165/00003495-200969070-00005.